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Abstract: Bone marrow (BM) is a reliable source of multipotent mesenchymal stromal cells (MSCs),
which have been successfully used for treating osteonecrosis. Considering the functional advantages
of BM-MSCs as bone and cartilage reparatory cells and supporting angiogenesis, several donor-
related factors are also essential to consider when autologous BM-MSCs are used for such regenerative
therapies. Aging is one of several factors contributing to the donor-related variability and found to
be associated with a reduction of BM-MSC numbers. However, even within the same age group,
other factors affecting MSC quantity and function remain incompletely understood. For patients
with osteonecrosis, several underlying factors have been linked to the decrease of the proliferation of
BM-MSCs as well as the impairment of their differentiation, migration, angiogenesis-support and
immunoregulatory functions. This review discusses the quality and quantity of BM-MSCs in relation
to the etiological conditions of osteonecrosis such as sickle cell disease, Gaucher disease, alcohol,
corticosteroids, Systemic Lupus Erythematosus, diabetes, chronic renal disease and chemotherapy. A
clear understanding of the regenerative potential of BM-MSCs is essential to optimize the cellular
therapy of osteonecrosis and other bone damage conditions.
Keywords: multipotent mesenchymal stromal cells; osteonecrosis; autologous bone marrow; regen-
erative therapy
1. Introduction
Bone marrow-multipotent mesenchymal stromal cells (BM-MSCs), the key bone regen-
erating cells, were first identified as attached to plastic culture surfaces and characterized
by a self-renewal capacity to form a colony and the ability to differentiate into bone, carti-
lage and fat cells [1]. With accumulating scientific knowledge on the MSC roles in tissue
regeneration, their other functions, including immunoregulation, proliferation, angiogen-
esis support and pro-survival abilities, became important to consider for application in
regenerative therapies [2–4]. The best-characterized and most frequently used source of
MSCs is BM, even with the very low frequency of these progenitor cells, i.e., 0.01–0.001%
of nucleated BM cells [1,5].
Osteonecrosis (ON), also named avascular necrosis, is a multifactorial and painful
bone disease characterized by vascular insufficiency, progressive collapse of subchondral
bone and cartilage damage. This disease often develops in the femoral head, but it could
also affect other joints, mostly in young or middle-aged individuals. One main mechanism
of ON pathogenesis is vascular damage due to clotting, embolism, increased intraosseous
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pressure and direct blood vessel injury [6]. ON can also be caused by direct trauma or infec-
tions. The most common non-traumatic conditions that can trigger ON are corticosteroids,
alcohol abuse, Gaucher’s disease, sickle cell disease, Systemic Lupus Erythematosus, dia-
betes, chronic renal diseases and chemotherapy (Figure 1) [6]. Over the last three decades,
autologous MSCs have attracted considerable interest as cellular regenerative therapies for
ON [7]. For enhancing therapeutic outcomes, it is also important to consider the effects
of patients’ age as ON is common among young and old populations but can occur in
elderly individuals according to the underlying conditions [7–9]. Here, we review how
these predisposing causes of ON and age can affect the biological characteristics of MSCs.
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Figure 1. nderlying causes and pathogenesis of osteonecrosis ( ). Chronic diseases can cause , such as sickle cell
disease, Gaucher’s disease, Systemic Lupus Erythematosus, diabetes, chronic renal disease and chemotherapy. Additionally,
corticosteroids and alcohol abuse are other triggers.
2. MSC Therapy for Osteonecrosis
2.1. Pre-Clinical Studies
Extensive experimental research (in vitro and in i st i s) s c fir t e
unique and ultifacete re e er ti iti f . f t ir i i l i-
l properties, MSCs repres nt a promising therap utic tool for ON (Figure 2). Importantly,
MSCs provide angi genic support function mostly due to the production of Vas ular en-
dothelial growth f ctor (VEGF) and control oste clastogenesis via th release of soluble
factors such as RANKL and OPG [10,11]. These cells also have essential differentiation
cap cities needed to r pair damaged bone and cartilage tissues in ON [12]. More recently,
th ir high proliferation and ability of suppression of immune respo se a s ciated with
tissue damage via the production of immu osuppressive factor , ndoleamine 2,3 dioxyg -
nase (IDO), Transforming growth facto -be a (TGF-β), prostaglandin E2 (PGE-2) and IL-10
have been consider d equally import nt [13–15]. A controlled inflammatory reaction is
required for the normal bone healing process and is deemed necessary for timely fracture
repair and tissue regeneration in ON [14].
An important factor in the therapy of ON is the use of 3D scaffolds that are used as
bone fillers and additionally support the repair functions of MSCs [16]. These scaffolds
also overcome the disadvantages of autografts and allografts, such as limited accessibility
and side effects of immune rejection and infection [16]. The needed criteria for scaffolds
used in regenerative therapies include biocompatibility, biodegradability, porosity, and
mechanical support to avoid bone collapse during the repair process. Several natural and
synthetic materials are used to fabricate scaffolds [16,17]. Polymers are commonly used
in ON treatment include as poly lactide-co-glycolide (PLGA), poly ε-caprolactone (PCL),
Cervi Cornus Colla (CCC), polyethylene glycol maleate citrate (PEGMC), polylactide (PLA),
polymethyl methacrylate (PMMA), and peptide-based hydrogels, but they lack mechanical
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stability [16]. Other materials include natural polymers, such as hyaluronic acid and colla-
gen reinforced with demineralized bone matrix (DBM), and inorganic components of bone,
e.g., calcium phosphate (CP), β-tricalcium calcium phosphate (TCP) and hydroxyapatite
(HA) [16]. Using porous HA or TCP scaffolds together with BM MSCs enhanced bone
regeneration in osteonecrosis, as seen in experimental models [18]. Popular materials for
synthetic scaffolds also include ceramics, bio-glass and porous titanium (Ti) [16].
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Figure 2. Functional characteristics of MSCs for therapeutic use in ON. MSCs can differentiate into bone or cartilage,
support angiogenesis via VEGF secretion, proliferate to compensate for bone cell death, regulate osteoclastogenesis via
RANKL and OPG and suppress inflammation associated with tissue damage via the production of immunosuppressive
factors IDO, TGF-β, PGE-2 and IL-10.MSC: mesenchymal stromal cells. IDO: indoleamine 2,3 dioxygenase.
In a composite approach, bioactive cells and growth factors are included to ‘func-
tionalize’ the scaffolds and enhance the osteoinductivity. A combination of scaffolds and
MSCs is a popular method to repair necrotic areas, as the scaffolds help direct MSCs to the
necrotic areas and deliver mechanical support for these cells. Ceramic scaffolds loaded
with BM-MSCs promoted the healing of bone defect in a canine model of femoral head
ON [19]. Porous tantalum scaffolds were used to load MSCs following surface cover with
Bio-Gide® collagen membrane [20]. This hybrid therapy has helped induce bone and
cartilage repair of femoral head necrosis in a rabbit model [20]. The seeding collagen
scaffold with hypoxia-pretreated BM MSCs induced bone regeneration and angiogenesis in
rabbit femoral head ON as hypoxia increase viability and osteogenic capacity of MSCs [21].
In addition to MSCs, more complex constructs can be potentially used as scaffolds loaded
with both adipose-derived MSCs and endothelial cells, shown as a potential therapy for
ON in a rat model [22].
Another successful approach for ON therapy is the use of scaffolds functionalized
by growth factors to ensure the sustained release of these factors, which would enhance
MSC regenerative functions and blood vess l for ation. This combination also solves
the problems of local application of growth fact rs, such as their hort half-life in vivo
or heterogenous ossification related to the applications of BMPs [23]. Encapsulation of
growth factors, such s BMP-2 or VEGF [24,25] in the PLGA micr sphere, showed great
results in exp rimental models f bone necrosis. Combined platelet-rich plasma (PRP) with
scaffold has been shown to have the c pacity to heal defects in a rabbit model of ON [26].
Another pot ntial tool include platelet-derived growth factors that can be us in different
formats. Allogeneic pl telet lysate or PRP prepared from young, h althy donors has a great
potential enhancing chondrogenic and osteogenic pote tial o MSCs. This combination
therapy is popularly considered for traumatic bone damage and various egenerative joint
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diseases [27,28]. In a case study, a combined local injection of adipose tissue-MSCs with
platelet-rich plasma showed satisfactory outcomes in an experimental model of femoral
head ON [29]. Another approach for enhancing MSC-based therapy is the use of genetically
modified MSCs. The bFGF- gene overexpressed lentivirus-transfected BM MSCs combined
with cancellous bone is one example that was tested in a rabbit model of ON with bone
healing success [30]. Furthermore, synthesized adenovirus-mediated BMP-2 and bFGF
modified BMSCs combined with DBM were effective in the repair of a canine femoral head
defect [31].
2.2. Clinical Studies
Initial studies on using autologous MSCs for the treatment of ON were based on
cultured MSCs from bone marrow (BM) aspirates and have demonstrated excellent patient
safety and efficacy profiles as proved by pain relief and radiological signs of healing [32,33].
A phase I/II study in sickle cell disease patients who had ON showed a high success rate
when using autologous MSCs up to 60 months of follow-up [34]. Similarly, Gangii et al.
showed that autologous BM-MSCs were effective to treat the early stage of ON for the
60-month follow up [35]. In common, the outcome of MSC-based therapy shows better
outcomes in the early stages of ON and traumatic rather than non-traumatic patients [36,37].
Using uncultured autologous MSCs are particularly preferred for ease of extraction,
safety and minimal need for handling, processing, and ethics [7]. Pioneering work by
Hernigou et al. of using BM autologous MSCs to treat patients with femoral head ON
in combination with core decompression has indicated the potential therapeutic value of
these cells, particularly in a dose-dependent fashion [38]. The same group showed that the
numbers of BM MSCs are reduced in ON and suggested better techniques to increase the
yield of harvested progenitor cells, such as optimizing the BM aspiration method and using
BM concentrates [39]. While the benefits of autologous BM MSCs in ON seem evident,
more focus on assessing the numbers and, particularly, the biological fitness of therapeutic
autologous MSCs is needed to develop these therapies further.
Core decompression is a classical surgical treatment for ON but usually effective
for small necrotic lesions. The combination of core decompression with autologous BM
was associated with improved clinical scores and radiological signs [40]. Some clinical
studies have included other supporting factors for MSCs. Injection of concentrated BM and
platelet-rich plasma was used for 77 ON patients and showed clinical improvement in 86%
of the tested group [41]. In another study, a combination of core decompression, autologous
BM-MSCs and calcium sulphate/calcium ceramic scaffold showed satisfactory outcomes.
However, that study lacked controls of single therapeutic tools [42]. Other functional
scaffolds were tested, and Kuroda et al. showed that using slow-release scaffolds to deliver
human FGF was an advantage to promote regeneration of bone necrosis in femoral ON
patients [43].
The BM is a common source for MSCs used for ON, and the clinical delivery of BM
MSCs as mononuclear cells was found to be better than using whole BM, likely because
of concentrated cells [44]. Adipose stromal cells were also applied into hip joints and
resulted in positive clinical outcomes [45]. In another study, a combination of umbilical
cord MSCs and BM mononuclear cells improved ON patient symptoms [46]. Furthermore,
the delivery of MSCs is commonly directed into the area of ON, but the systemic infusion
could be another route of delivery. Co-infusion of BM cells and umbilical cord MSCs
through femoral artery resulted in clinical improvement as conducted in Phase I/II clinical
study on 30 femoral head patients [46]. Additionally, Mao et al. found that intra-arterial
MSCs was effective in treating early-stage ON [47]. However, additional research is still
required to determine whether the local delivery or the systemic infusion of MSCs is more
effective in ON therapy.
In summary, the great potential of autologous MSCs alone or in combination with
scaffolds and growth factors for tissue repair in ON is evident [6,48]. However, different
ON-underlying factors could hamper the regenerative potential of autologous MSCs. As
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there are multiple causes for the development of ON, it is essential to assess the patient’s
suitability for autologous MSC use carefully and consider how the underlying cause of ON
might affect the biological fitness of these regenerative cells. This knowledge will help to
optimize autologous MSC-based regenerative therapies for ON. Furthermore, the effect
of a patient’s age should be taken into account based on the recent advances in this area
of research.
3. Age-Related Changes in MSCs
ON is common in the young/middle age group [7,49]. While chronological aging
is related to the numbers of years, the process of biological aging can be promoted by
environment, diet, disease, heredity and lifestyle [50]. At the cellular level, aging is a
complex process caused by an accumulation of various types of damages in cells over
time [51,52]. The free radical theory refers to the damage caused by intermediate oxygen
molecules resulting from cellular metabolism. In older age, oxidative stress outgrows
the level of anti-oxidant enzymes resulting in increasing levels of reactive oxygen species
(ROS) [53]. Another theory suggests that replication errors and extrinsic factors (such as
radiation and ROS) progressively cause damage to the DNA, ultimately leading to cell
senescence or death [50,54,55]. These general theories apply to MSC ageing characterized
by a decline in their number [56], increased ROS leading to a shift towards adipogenic
differentiation [57], a decline in telomere length [58], as well as increased DNA damage [59].
3.1. Pre-Clinical Studies
Previous in vitro studies have used the long-term passaged MSCs in vitro as an indi-
cation of ageing. These studies showed that several changes are associated with in vitro
ageing of MSCs [60]. These changes include reduced survival and proliferation, increased
senescence and ROS expression levels, decreased differentiation potential, and increased
genetic instability [60]. However, recent studies on MSC healthy aging in vivo (as discussed
below) could change our understanding of aged MSCs and their use in therapy for ON.
3.2. Clinical/Human Studies
The CFU-F assay has been the oldest method for enumerating BM-MSCs by count-
ing the numbers of single cell-derived colonies based on first the MSC ability of plastic-
adherence and second their ability to proliferate forming a colony. Over the years, several
groups have performed CFU-F experiments to examine the age-related changes in the
number of aspirated iliac crest BM-MSCs (Table 1). The variable results obtained can be
due to different factors. For example, different volumes of BM aspirates have been used
(Table 1), but larger-volume aspirations could lead to the dilution of BM aspirates with
blood [61] and subsequently produce artificially low MSC frequencies, as MSCs are not
present in the peripheral blood [62,63]. Further processing of the BM aspirate for MSC
isolation as well as using different media and different scoring criteria, could also impact
the CFU-F frequency [64–66] (Table 1).
Irrespective of these compounding factors, a general trend for a decline in BM MSC
numbers has been confirmed in several recent studies. Most recent data from our labora-
tory (n = 67 donors, 33 females and 34 males) indicated a significant age-related decline in
the number of colonies in relation to donor age in both males and females [73]. Interest-
ingly, while the overall median CFU-F frequency was the lowest in the old donor group
(61–89 years old), the decline was the steepest between young donors (19–40 years old)
and the donors of the intermediate age group (41−60 years old) [73]. Similarly, another
study has found a decline with age, but no groups were analyzed [74]. This was also noted
in the study by Siegel et al., which implied that the decline in MSC numbers begins in the
fifth decade of life [56].
Enumeration of uncultured BM-MSCs has also been attempted by flow cytometry
using several surface markers [75–77]. CD271 (low-affinity nerve growth factor receptor) in
combination with CD45 (pan-hematopoietic lineage cell marker) has been recently reported
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to provide the best gating strategy for BM-MSCs [77–79]. In two of our recent studies, BM-
MSCs were quantified volumetrically using the CD45lowCD271+ phenotype [72,73], and in
both studies, we observed trends for age-related decline in the numbers of MSCs [72,73].
However, a steeper decline was observed in the intermediate age group (41–60 years old)
as compared to the young donor group (19–40 years old), rather than in the donors of the
old age group (61–89 years old) compared to the intermediate age group, in agreement
with CFU-F findings [73]. Overall, these studies indicate that autologous MSCs in relatively
young ON patients are likely to be higher in number compared to those from the middle-
age group.
Table 1. List of previous studies investigating age-related changes in the numbers of BM MSCs counted by the CFU-F assay.
Age (Years) Volume (mL) Isolation Media ColonyDefinition CFU-F Ref
Y: 22–44, O: 66–74 10 mL DC α-MEM + 10%FCS >16 cells No change [67]
13–79, no groups 4 × 2 mL pooled DC α-MEM + 10%FCS + ASC + Dex >8 cells No change [68]
Y: 0–18, O: 59–75 NR DC DMEM + 10%FCS NR Decline [58]
Y: 19–40, O: >40 NR DC DMEM + 10%FCS >50 cells Decline [69]
Y: 6–16, O: 29–76 NR PA DMEM + 20%FCS NR NS decline [70]
1–52, no groups NR DC DMEM + 20%FCS >50 cells No change [71]
22–80, no groups 8 mL PA StemMacs medium >50 cells Decline in women [72]
Y: 20–40, I: 41–60, O: >60 10 mL PA StemMacs medium >50 cells Decline [73]
14–59, no groups 30 mL, 3 × 10 mL PA DMEM/Ham’s F12 + 10% FCS +bFGF + heparin >50 cells Decline [74]
Y: <45, I: 45–65, O: >65 NR DC α-MEM + 10% human serum >50 cells Decline [56]
BM: Bone marrow, I: intermediate, O: Old, Y: Young, PA: Plastic adhesion, DC: Density centrifugation α-MEM: Alpha–Minimum essential
medium, DMEM: Dulbecco’s minimum essential medium, FCS: Fetal calf serum, ASC: sodium ascorbate, Dex: dexamethasone, bFGF: basic
fibroblast growth factor, NR: Not reported, NS: Non-significant.
Using uncultured MSCs, our group has recently shown no significant age-related
increase in adipogenic or osteogenic differentiation transcripts or ROS levels in uncul-
tured MSCs from old donors compared to young donors [73,80]. This contrasts with the
higher ROS levels found in minimally cultured MSCs from older donors [81]. Very re-
cently, another group evaluated the number and functionalities of MSCs from young and
old donors and found no age-related differences in growth kinetics, tri-lineage potential,
gene expression profiles and immunosuppressive properties [82]. When the same biologi-
cal characteristics were compared between early and late passage MSCs, they displayed
significant differences. Although this indicted little implication of donor age on MSC im-
munomodulatory functions, more research would be needed to assess this function in other
ON-underlying diseases. This research will be particularly important for therapeutic MSCs
as defective immunosuppression has been recently reported with a link to complicated
bone healing [83].
The age-related changes of the extra cellular matrix (ECM) could affect the functions
of MSCs and their use for ON therapy [84]. The ECM is formed of proteoglycans, fibrous
proteins (mainly collagens), minerals and water. In joints, proteoglycans absorb water
and act primarily to resist load compression and create flexibility. In contrast, collagens
enable cartilage to resist sheer stress. With aging, changes in these ECM components
can lead to osteochondral tissue damages. As the age increases, the molecular weight
of proteoglycans is decreased, and the proteolytic enzyme activity is increased [85,86],
leading to reduced proteoglycan aggregates and higher levels of serum aggrecan frag-
ments [87]. Similarly, thickness and cross-linking of collagen type II fibers are detected
with aging [85]. Furthermore, an age-mediated increase in the expression and activity of
collagenase activity by chondrocytes could lead to articular surface fibrillation and ero-
sion [88]. Such disturbance in ECM homeostasis could affect the reparatory performance of
intrinsic or implanted therapeutic MSCs as ECM is essential for cell survival, proliferation
and communication. Collagen type II enhances chondrogenesis and osteogenesis of MSCs
by facilitating osteogenic marker RUNX2 stimulation via the integrin α2β1-FAK-JNK sig-
naling pathway [89]. Another component of ECM proteoglycans, Syndecan-1, is involved
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in osteo-adipogenic balance during the early induction of MSC lineage differentiation [90].
In addition to ECM, an inflammatory microenvironment such as that seen in osteoarthritis
can also negatively affect MSC function by suppressing chondrogenic and osteogenic
differentiation [91]. Consequently, it is important to consider the joint microenvironment
to optimize MSC-based therapy for ON, particularly in aged patients. Suggestions of using
young ECM to rejuvenate therapeutic MSCs also necessitates further investigations [92,93].
Summarizing the current literature in relation to age-related changes in BM-MSCs,
it becomes apparent that young individuals are likely to have several-fold more MSCs in
aspirated BM compared to donors over 40 years old. This can have implications on the dose
of MSCs delivered into the damaged femoral head in ON patients. However, middle-aged
and older donors show significant variability in relation to their MSC numbers, possibly
because their skeletal biological ages are not the same as their chronological ages and may
have been affected by environmental causes listed at the beginning of this section. With
regards to MSC functions, such as differentiation, anti-oxidative and bone-remodeling
capacities, age-related declines reported using cultured MSCs may represent an artefact
of culture-expanded in vitro, and different types of assays need to be developed for the
assessment of these functions in uncultured MSCs. In relation to ON treatment with
autologous MSCs, these findings indicate that MSC dose-determination based on rapid
laboratory tests [72], rather than ‘predicted’ from patients age, is needed for standardization
of these therapies.
4. The Effect of Glucocorticoids on MSCs
Physiological Glucocorticoids (GC) hormones are produced by the adrenal cortex,
bind to their cell receptors and, consequently, transport to DNA, modifying cell biology.
Although GC therapies are commonly used for anti-inflammatory effect, their significant
immunomodulation could trigger undesirable effects that impair bone biology, causing
osteoporosis [94]. Additionally, GC-based therapy is a major cause for developing ON,
with a 5–25% prevalence among non-traumatic ON cases [94,95]. The risk of developing
ON is known to increase with long-term, high-dose and intra-articular administration of
GC [96,97]. Different mechanisms of GC-induced ON have been described, particularly the
decrease of the production of osteoblasts and osteoclasts, the induction of the apoptosis of
both cells and the damage to the blood supply of bones [96,97]. Additionally, it has been
shown that patients who have these medications display reduced BMP2 and osteocalcin
gene expression in BM stromal cells and are very likely to develop ON [98].
4.1. Pre-Clinical Studies
The effect of GC on MSC biology was investigated in the cells of several experimen-
tal models as well as human cells ex vivo. BM-MSCs of age-matched rats were treated
in vitro with various concentrations of 17 β-estradiol and dexamethasone. Interestingly,
the data showed that these steroids changed MSC proliferation and differentiation in a
dose-dependent manner. A low dose of these steroids helped to enhance MSC prolifera-
tion and osteogenic differentiation as noted by an upregulation of alkaline phosphatase
(ALP), osteocalcin (OCN) and calcium levels as well as TGF-β1 and BMP-7 transcripts.
However, a high dose of these steroids inhibited MSC differentiation and proliferation [99].
Therefore, low doses of dexamethasone are commonly used in specialized culture media to
enhance the in vitro osteogenic, adipogenic and chondrogenic differentiation of MSCs [100].
Interestingly, effective doses to enhance MSCs osteogenic potentials and growth factor
expression were different between males and females and likely related to the different
expression levels of steroid receptors between both genders [99]. The gender-related dif-
ferences have been noted for brain and endothelial progenitor cells [101,102]. However,
further investigations for such receptor differences, and consequently, therapeutic consider-
ation would be needed for human BM-MSCs. Nuzzi et al. have tested the effect of different
GC drugs, including triamcinolone acetonide, alcohol-free triamcinolone acetonide, mi-
cronized intravitreal triamcinolone and dexamethasone on human BM-MSCs. Similar to
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animal studies, GC exerted a negative effect on the viability and growth rate of healthy
BM-MSCs, as well as changes in the cell morphology [103].
GC was also found to upregulate the Dickkopf1 (DKK-1) levels that inhibit the os-
teogenic Wnt/β-catenin signaling pathway in BM-MSCs, leading to bone resorption [104].
Similar to BM-MSCs, adipose tissue-derived MSCs exposed to GC demonstrated a lower
ALP activity, with high serum DKK-1 levels detected in steroid-induced ON patients [104].
Interestingly, a miRNA microarray analysis on ON-MSCs or GC-treated MSCs showed that
miRNA-708 was upregulated and associated with the suppression of SMAD3 and RUNX2
expression, and consequently, the osteogenic potential of MSCs, but with an enhancement
of their adipogenesis [105] which might contribute to fatty bone marrow, a typical char-
acter of ON. GC can also inhibit the immunoregulatory effect of MSCs. An in vitro work
showed that dexamethasone could reverse MSC-mediated inhibition of T-cell proliferation
in a dose-dependent manner [106]. This dexamethasone effect is mediated by interfering
with STAT1 phosphorylation and subsequently cause a reduction of an anti-inflammatory
mediator, inducible nitric oxide synthase (iNOS) [106]. Furthermore, a mouse model of
liver fibrosis showed effective anti-inflammation signs such as decreased T-lymphocyte
infiltration when treated by MSCs alone. However, simultaneous administration of dexam-
ethasone abolished these therapeutic effects of MSCs [106]. Control of inflammation at the
early phase of bone healing, in which MSCs are involved, is essential to progress into an
effective healing phase [107–112]. Considering that MSCs and other immunosuppressants
could counteract each other, particularly for immunoregulation, simultaneous application
of MSCs with GCs might have an adverse effect on bone repair.
4.2. Clinical/Human Studies
Human BM samples from individuals with GC-induced ON had lower CFU-F num-
bers compared to two groups of those with ON related to sickle cell disease and healthy
controls [113], further confirming the suppressive role of GC on MSC proliferation.
In patients receiving systemic GC, a significant drop of serum sclerostin, OPG and
OCN levels were observed. However, an increase of type 1 collagen cross-linked C-
telopeptide, which were positively correlated with DKK-1 levels, were noted [114]. To-
gether, these data suggest a negative effect of GC on bone formation potential. Effects of
excess doses of GC are equally seen in patients with Cushing syndrome with increased fat
deposits and osteoporosis [115].
Overall, a systematic effect of GC treatments on BM-MSCs is highly probable, poten-
tially causing a reduction of their numbers in vivo. Nevertheless, more studies are needed
to confirm this GC effect, particularly considering additive aging-related reduction of MSC
numbers. In addition, impairment of repair function may be expected; therefore, boosting
MSC osteogenic pathways are highly desirable in these cases. For example, targeting
DKK-1 in MSCs before being used for regenerative purposes could be the solution. It is also
of value to include other tools of therapeutic regeneration, such as tissue growth factors.
For example, using bFGF releasing scaffolds in the dexamethasone-induced ON rat model
allowed increased cartilage regeneration without cytotoxic effects on MSCs [116].
5. Alcohol Effects on MSCs
Chronic and heavy alcohol intake is a high-risk factor for secondary osteoporosis, bone
mineral density loss, and bone remodeling impairment. Consolidate evidence showed
that bone turnover and healing is negatively affected by alcohol [117,118]. For ON, alcohol
is one of the common non-traumatic underlying causes. Chronic alcohol consumption is
usually associated with an increase in serum triglyceride and cholesterol levels, and these
could lead to the death of bone-forming cells and disturbance of bone remodeling and,
eventually, osteonecrosis [119].
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5.1. Pre-Clinical Studies
Studies on in vitro expanded human BM-MSCs indicated the damaging effects of
alcohol on various MSC biological functions, particularly proliferative capacity that can
translate into low in vivo counts. Alcohol induces senescence in BM-MSCs, which grad-
ually lose self-renewal potential and are known to exhibit impaired multi-lineage differ-
entiation potentials that will reduce the rate of bone formation and raise the osteoporosis
risks [120,121]. Chen et al. tested the culture-expanded BM-MSCs exposed to a high
ethanol concentration and showed a reduction of the proliferation and increase of the
senescence of these cells [122]. The reduction of MSC count in cultures was measured by
microscopy together with G0/G1 cell cycle arrest and upregulation of cell cycle regulators,
p16INK4α and p21 levels. These alcohol-treated MSCs also showed premature senescence
in a dose-dependent manner with an increase in β-galactosidase (β-gal) expression de-
tected by fluorescence microscopy and changes in senescence-related genes; a reduction of
silent information regulator Type (SIRT1) gene, which also controls the osteogenic commit-
ment of MSCs and an increase of proliferation controlling gene, P38 [122]. Additionally,
chronic exposure to alcohol in adult rat for 12 weeks demonstrated that BM-MSCs from
femur and tibia and adipose-derived MSCs had low proliferative capacity, as shown by
the CFU-F assays [123]. Consistently, cord blood progenitor cells displayed an increased
β-gal activity and shortening of telomere linked to the decrease in SIRT1 when treated by
alcohol [124]. In contrast, the overexpression of SIRT1 in these cells restored non-senescent
phenotypes [124].
In terms of differentiation, chronic alcohol consumption decreases the bone-forming
capacity and conversely increases the adipogenic differentiation of BM-MSCs [125]. Ad-
ditionally, BM-MSCs exposed to ethanol in vitro have shown a significant reduction of
collagen type I expression and ALP activity [126]. As shown in a mouse model, these
effects are related to the activation of mammalian target of rapamycin (mTOR) signaling cas-
cade, causing downregulation of RUNX2 and increase of peroxisome proliferator-activated
receptor-gamma (PPAR-γ) via the activation of p70 ribosomal protein S6 kinase. Con-
versely, blockage of the mTOR pathway by rapamycin treatment improves alcohol-induced
MSC osteogenic differentiation and osteopenia [125]. Deregulation of Wnt signaling due
to alcohol exposure could be another mechanism of impairment of MSC differentiation,
and an incomplete healing process persists up to two weeks post-fracture [127]. Chronic
alcohol exposure had an effect on fracture healing with decreased mineralization, as re-
ported in different experimental studies [128–130]. Testing the mineralization using alizarin
red and perchloric acid staining as well as measuring osteoblast-specific genes, RUNX2,
BGLAP and COL1A1, revealed that ethanol-treated MSCs had a significantly lower os-
teogenic capacity due to downregulation of the SIRT1 gene [131]. Other experimental
studies have reported that episodic or acute alcohol exposure in rodents negatively affects
cartilaginous callus development mainly due to inhibition of canonical Wnt/β-catenin
signaling [127,132–138]. Another mechanism of alcohol-related impairment of cartilage
and bone healing is the downregulation of TGF-β1 protein expression via interference with
the transcription factor myeloid zinc finger 1, as shown in vitro for human BM-MSCs [139].
Several research groups indicated that alcohol exposure could also decrease callus biome-
chanical strength [132,134,135]. It has also been demonstrated that mice injected with
ethanol in a similar pattern of heavy episodic drinking had decreased callus size and
biomechanical stiffness [140].
In an experimental study, alcoholic rats showed decreased serum levels of certain
inflammatory markers, interleukin (IL)-6, IL-2, IL-10, and C-reactive protein after in-
duction of femoral mid-diaphyseal closed fracture as well as reduction of white blood
cell numbers compared to saline-injected rats [141]. Additionally, alcohol could modu-
late the local fracture microenvironment enhancing proinflammation, and the fracture
healing in alcohol-exposed animals was found to be enhanced using IL-1 and TNF an-
tagonists [130]. Therefore, although no studies have explored the direct effect of alcohol
on the immunomodulatory functions of MSCs, it is possible that these MSC functions
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are, consequently, affected by alcohol-related proinflammatory changes. Regarding MSC
migration, alcohol might reduce osteopontin (OPN) protein expression as well as integrin
β1 receptor expression levels that are largely involved in MSC homing following bone
trauma [140,142].
5.2. Clinical/Human Studies
One recent study has compared the numbers of MSCs in BM concentrates from three
ON patient groups: alcohol, GC and trauma. Similar numbers of MSCS measured by
CFU-F assay were reported for the three groups [143]. Although the study indicated not
much role for alcohol and GC compared to trauma, an ideal comparison should include
healthy controls. Additionally, using another method to count MSCs (e.g., CD271+ cell
counts via flow-cytometry) and normalization of some differences in fold-enrichment of
MSCs in BM concentrates would be needed to confirm the effect of ON causes on MSC
quantity/proliferation.
In summary, chronic alcoholism has a detrimental effect on several MSC regenerative
functions. Therefore, growing research aims to improve these functions. Anti-oxidant
therapies, e.g., N-acetylcysteine and Vitamin D, have been proposed as therapeutic tools to
prevent or minimize the negative effect of alcohol intake on bone healing, as reported in an-
imal studies [144,145]. While the effects of chronic alcohol intoxication on bone remodeling
are not permanent and can be improved after two years of discontinuing alcohol consump-
tion stopping [146], a further understanding of the molecular mechanisms involved in the
development of alcohol-induced effects may help to identify new therapeutic targets to
optimize MSC-based therapies.
6. MSCs in Sickle Cell Disease
Sickle cell disease (SCD) is a red cell disorder associated with various vascular patholo-
gies, capillary damages and a high prevalence of bone involvement [147]. Adesina et al.
have reported that a 22% percentage of SCD patients can develop ON, particularly in
patients with severe forms of the disease, in elderly patients and those with comorbidity of
acute chest syndrome [148]. The pathogenesis of SCD-related ON is mostly related to the
clotting or the occlusion of micro-vessels of bones [149,150].
6.1. Pre-Clinical Studies
The experimental mice model for SCD is usually used to understand the pathogenesis
and test the gene therapy for this disease [151]. No animal studies testing SCD effect
on MSCs.
6.2. Clinical/Human Studies
In one study, the proliferation of MSCs from SCD patients was similar to that of
healthy MSCs as tested by the in vitro doubling time and the surface marker phenotype.
Isolated MSCs from BM aspirate concentrates of these patients maintained their prolifera-
tive potential and chondrogenic, adipogenic and osteogenic differentiation potential [12].
Furthermore, SCD culture-expanded MSCs were found to produce osteogenesis cytokines
and growth factors, IL-8, TGF-β1, SDF-1 and VEGF [34]. Hypoxia-preconditioning of SCD
BM-MSCs was found to increase the production levels of trophic factors (VEGF, IL8, MCP-1
and ANG) mediating angiogenesis and tissue repair [152].
In addition to repair functions, SCD MSCs have also been shown to preserve im-
munoregulatory capacity, with IDO found to be the major immunoregulatory media-
tor [151]. Interestingly, CFU-F counts and CD271 + CD45-/low cells in BM concentrate
were significantly higher in SCD than in SCD-unrelated ON patients [153]. However, the
authors reported an age-related reduction of these numbers. Additionally, similar differ-
entiation potential and secretion of cytokines were noted between the two groups [153].
A recent study by Daltro et al. showed that pediatric SCD has, on average, 27 CFU/106
nucleated BM cells, with a satisfactory outcome when used for ON therapy [154]. In view
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of these data, it could be proposed that the younger the SCD patients, the better outcome
of using autologous BM MSCs. However, further studies comparing matched-age groups
would be needed to confirm the effect of SCD on MSC biology.
Considering their preserved functionality and proliferative potential, autologous
MSCs were used in phase I/II, non-controlled studies of 89 SCD patients with ON via
local implantation of BM aspirate concentrate [34,155]. The clinical data showed that SCD
patients who received this cellular treatment had a significant pain relief measured by
the Harris Hip score and without deterioration of early stages of ON [34,155]. Together,
these data proved the safety and effectiveness of the BM-MSC-based autologous therapy,
particularly for the early stages of ON in SCD patients.
7. MSCs in Gaucher Disease
Gaucher disease (GD) is commonly associated with bone abnormalities such as os-
teoporosis, ON or pathological bone fractures [156]. The mechanisms of ON-related bone
abnormalities include the accumulation of abnormal cells which infiltrate the BM compart-
ment, causing bone damage [157].
7.1. Pre-Clinical Studies
An experimental study using a mouse model of GD demonstrated that the skeletal
manifestations of this disease are connected to an impairment of MSC proliferation. Addi-
tionally, a decrease in the osteogenic potential of GD MSCs in this model was shown by
low ALP and RUNX2 gene expression levels [158].
7.2. Clinical/Human Studies
MSCs from one adult patient with GD was tested for the phenotype and functions of
MSCs. These MSCs displayed standard MSC surface markers as well as normal osteogenic
and adipocytic differentiation and growth. However, these MSCs showed an altered in-
flammatory secretome with a marked increase in COX-2, PGE2, interleukin-8 and CCL2
production relative to the normal controls [159]. These preliminary data indicated an abnor-
mal immunoregulatory role of GD MSCs that could reflect on bone healing. Furthermore, a
larger study including 10 patients reported that GD MSCs showed a defective proliferative
potential, cell cycle abnormalities, and importantly, impaired osteogenic differentiation as
measured using ALP activity and OPN levels. Additionally, GD MSCs have significantly
upregulated levels of osteoclast inhibitor and bone lytic mediators, PGE2 and DKK-1,
respectively [160].
Together, these data suggest defective proliferation and differentiation. More pre-
clinical and clinical studies on the potential use of autologous MSCs in the treatment of
GD-related ON are highly needed.
8. MSCs in Systemic Lupus Erythematosus
A high prevalence of ON in Systemic Lupus Erythematosus (SLE) has been reported,
with nearly 37% of lupus arthritis patients eventually developing ON [8]. The main mecha-
nisms that lead to ON are believed to be the therapeutic use of GC [161], immunosuppres-
sive drugs [161,162], altered lipid metabolism and thrombophilia due to anti-phospholipid
antibodies [8].
8.1. Pre-Clinical Studies
BM-MSCs from a lupus mouse model have shown proinflammatory rather than
inhibitory phenotype when stimulated by IL-1 and TNF-α. In these MSCs, there was an
increase in the expression levels of CCL19, VCAM1, ICAM1, TNF-α and IL-1β, together
with induction of CD4T cells proliferation [163]. Furthermore, BM-MSCs from a lupus
mouse model showed impairment in inhibiting B cell proliferation and differentiation,
mediated by the downregulated CCL2 levels [164].
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Several mechanisms have been proposed for SLE-related senescence and apoptosis
of MSCs. The abnormalities of SLE BM-MSCs have been linked to abnormal JAK-STAT,
Wnt/β-catenin, P53/P21 and PTEN/Akt signaling pathways in both human and mouse
studies [165–167].
8.2. Clinical/Human Studies
Cultured BM-MSCs from SLE patients displayed early senescence by increased β-gal
activity, cell cycle arrest, disordered F-actin distribution and/or downregulated telomerase
activity [165,166,168].
MSCs from SLE also express standard surface markers CD44 and CD105 and lack
CD14, CD34, CD45 and HLA-DR. However, these MSCs had downregulation of IL-6,
macrophage colony-stimulating factor (M-CSF) and IL-7 transcripts [169], indicating an
impairment of immunoregulatory functions. High serum levels of proinflammatory media-
tors, IL-6, IL-10 and TNF-α, are evident during SLE disease activity [170]. These cytokine
alterations could be linked to decreased of MSC proliferation or osteogenic differentiation
in SLE patients [171].
Shi et al. found that MSCs from SLE patients demonstrated a defective migration
capacity using the trans-well assay. Additionally, fluorescence microscopy images showed
an abnormal over-polymerization of the F-actin cytoskeleton, accompanied by a high level
of intracellular ROS. When these MSCs were treated with anti-oxidant N-acetylcysteine,
F-actin restored conformation and enhancement of the migration was noted [172]. An-
other mechanism included MiR-663 that could downregulate TGF-β1 and consequently
contribute to inhibiting the proliferation, migration and immunoregulation functions of
SLE BM-MSCs [173]. Considering their limited immunosuppressive potential, autologous
BM-MSCs used for therapy of SLE were not effective in controlling the disease activity [141].
In summary, BM-MSCs in SLE patients have low proliferation, and this could affect
their quantities in vivo. The use of these BM-MSCs as autologous therapy for ON should
also consider the other biological defects of these cells, including reduced differentiation
and migration abilities. In a recent study, culture-expanded autologous MSCs were ap-
plied to treat ON patient with comorbidity of SLE [174]. The clinical data showed no
adverse effects, preserved hip function and reduced pain in these patients [174]. However,
more clinical studies testing the clinical safety and effectiveness of native SLE BM-MSCs
are needed.
9. MSCs in Diabetes
Although diabetes has not been linked to ON as an underlying factor, the simulta-
neous existence of both conditions is common, particularly in elderly patients or diabetic
individuals who are treated with long-term GC [9]. Furthermore, diabetes has been linked
to the ON of the jaw in experimental models and patients. This link was mainly explained
by increased inflammation, altered immune responses and vascular damages associated
with diabetes and its medications [175].
9.1. Pre-Clinical Studies
Several functional properties were tested for diabetic BM-MSCs and found to be
defective. High serum concentrations of TNF-α in diabetic mice was directly linked to
low expression of Indian hedgehog (Ihh) in MSCs and, consequently, suppression of MSC
expansion and bone regenerative potential [176]. Interestingly, local delivery of purified
Ihh to the fracture site via a slow-release hydrogel-rescued proliferation of MSCs [176].
Kim et al. showed that the gene expression of angiogenic factors, VEGFs and an-
giotensin were reduced in diabetic MSCs, which, when cocultured with endothelial cells,
showed significantly lower endothelial tube formation [177]. The growth factors linked
to bone healing were reduced when tested in diabetic rodents’ models. A low VEGF
expression in the plasma and callus tissue, with poor micro-vessels and high chondrocyte
apoptosis in the fracture callus, was seen in diabetic mice [178]. Another group reported a
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significant association between reduced levels of serum VEGF and delayed fracture healing
in diabetic rats [179]. Other growth factors involved in bone healing FGF-2 and IGF-1 were
significantly decreased in serum and callus of tibial fracture in diabetic rats. These rats
also displayed a lower density and area of new bone [180]. However, expression levels or
response of MSCs to altered levels of these growth factors in diabetic patients remain to
be established.
The osteogenic differentiation of MSCs in a diabetic rat was reported to be impaired
compared to control MSCs, as measured by calcium deposition [177]. Furthermore, im-
paired bone healing, together with lower OCN levels, was found in a critical-sized bone
defect model in type 2 diabetes rats as compared to controls [181]. The delayed fracture
healing in type 2 diabetes is also associated with a differentiation switch from osteoblasts to
adipocytes, as seen in an experimental diabetes model [182]. The diminished osteogenic ca-
pability of MSCs was further proved by the low gene expression of osteogenic transcription
factors during bone healing in experimental models [183,184]. Human bone MSCs exposed
to high glucose concentration showed induction of PPAR-γ and ADIPOQ transcript ex-
pression levels during adipogenic differentiation in vitro. This adipogenesis induction was
associated with a significant rise of intracellular and extracellular ROS concentrations as
well as stress-related NOX4 gene under these diabetic-like conditions [185].
With regards to immunoregulation, a recent study using a diabetic mice model has
suggested a link of diabetes to the altered MSC-mediated immunoregulation. Bone MSCs
showed an aberrant nuclear factor-kB (NF-kB) activation, reducing TGF-β1 expression
in association with defective macrophage (M2) polarization and substantially enhanced
inflammation in diabetic [186]. Furthermore, inhibition of NF-kB in these MSCs or exoge-
nous TGF-β1 treatment reversed such detrimental proinflammatory effects on fracture
healing when persistent [186]. TNF-α is one of the proinflammatory markers that can
be markedly increased in diabetic, hyperglycemic and insulin-resistant mice [187]. The
diabetes-mediated proinflammation could trigger the chondrocyte apoptosis and, conse-
quently, reduce cartilaginous callus [188]. Additionally, TNF-α via FOXO1 transcription
factor caused an impairment of endothelial cell proliferation and downregulation of VEGF
gene expression in mice with long fractured bones, impairing their healing [189].
9.2. Clinical/Human Studies
Compared to pre-clinical studies, less research was conducted on the characterization
of human MSCs from diabetic patients. In a recent study directly comparing MSCs from
type 2 diabetes to age-matched MSCs from a healthy donor, it was concluded that diabetes
seems to affect the numbers but no functional capacities of MSCs [190]. CFU-F assays
were used to enumerate BM MSCs, and other functional assays included proliferation,
tri-lineage differentiation and angiogenesis support [190].
Additionally, MSCs from adipose tissue samples of type 2 diabetic patients induced
lower suppression of PBMCs proliferation, declined expression of anti-inflammatory TGF-
β1 and increased expression of proinflammatory mediators, TNF-α and IL-6 [191]. These
data suggested an impairment of diabetic MSC immunomodulatory effect that can affect
early phases of bone healing [83].
Collectively, diabetic-MSCs showed impairment of proliferation, angiogenesis-support,
osteogenesis, enhancing adipogenesis and immunoregulatory potential. These defects
should be considered to improve the outcomes for ON lesions in diabetic patients. The
biological stimulation of MSCs in diabetic patients has been proposed as a potential thera-
peutic strategy to improve the outcomes of using these MSCs for bone healing [176]. The
exposure to recombinant BMP-2/7 only or with IGF-1 prevented these changes in high
glucose cultures and significantly enhanced gene expressions of type 1 collagen and OCN
while suppressing that of the adipogenic marker PPAR-γ [192]. These data suggested the
potential value of combining with growth factors to optimize therapeutic MSC outcomes
for diabetes patients [192]. More research was conducted aiming to overcome the impaired
vasculature problem during fracture healing in diabetic patients. Using VEGF and FGF
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helped to rescue low expression levels of OCN and RUNX-2 and to improve angiogenesis
and healing of bone in diabetic mice [193]. Using microRNA to inhibit the pro-oxidant
protein p66, which promotes mitochondrial ROS generation, can consequently improve the
angiogenesis-supportive potential of the MSCs [194]. Another work by Bae et al. confirmed
that oxidative stress caused angiogenic dysfunction in diabetic BM-MSCs. The inhibition
of functionality of NADPH oxidase successfully increased angiogenic activity in these
experimental BM-MSCs [195].
10. Chronic Kidney Diseases Effects on MSCs
Chronic kidney diseases have been linked to ON, particularly of the jaw, with aging
and low renal function [196] in addition to children with chronic renal failure [197]. Dif-
ferent mechanisms have been proposed linking chronic kidney diseases to ON, including
using bisphosphonate and immunosuppressants after renal transplantation [198].
10.1. Pre-Clinical Studies
BM-MSCs derived from chronic kidney disease rats demonstrated premature senes-
cence as indicated by the upregulation of β-gal activity, spontaneous adipogenesis, reduced
growth rate and accumulation of actin [199]. Additionally, the MSC immunoregulatory
effect was tested in vivo in a mouse model of nephritis, showing no immunosuppressive
effect, unlike healthy MSCs [199]. Further studies to assess MSC functional capacities are
needed before considering autologous MSC therapy in renal disease-related ON.
10.2. Clinical/Human Studies
Even though several clinical studies have assessed the safety and outcomes of using
autologous MSCs for the treatment of mixed cause ON [33,34,155,200–203], a special focus
on individualized response to therapy when chronic kidney disease is the underlying cause
is essentially needed.
11. Chemotherapy Effects on MSCs
Chemotherapy is one of the reasons that can increase the risk of ON, most com-
monly in male patients receiving chemotherapy for testicular cancer and those treated by
chemotherapy for breast, ovarian, small-cell lung cancers and osteosarcoma [204]. The
mechanisms include the death of osteocytes, clotting and damage of blood vessels.
11.1. Pre-Clinical Studies
The effect of anti-cancer chemotherapy on MSC biology has been studied in differ-
ent reports. An in vitro study tested the functions of BM-MSCs that were treated with
chemotherapeutic agents used to treat leukemia such as cytarabine, daunorubicin and
vincristine. These MSCs showed reduced viability, osteogenic, chondrogenic and adi-
pogenic differentiation. Interestingly, these MSCs also showed decreased expression of
cell surface receptors CD90 and CD73 but increased expression of inflammatory cytokines,
IL-6 and TNF-α [205]. Another in vitro study tested the effect of chemotherapeutic medica-
tions usually used for bone marrow transplantation. The data showed that human MSCs
were resistant to apoptosis induced by busulphan, cyclophosphamide and methotrex-
ate). However, MSCs were relatively sensitive to paclitaxel, vincristine, etoposide and
cytarabine [206]. Nicolay et al. reported that human BM-MSCs are sensitive to bleomycin-
mediated apoptosis and reduced adipogenic differentiation relative to adult fibroblasts.
In contrast, the morphology, surface marker expression and migration potential showed
no alterations [207]. These in vitro studies indicated variable effects of chemotherapeutic
medications, but mainly on cell survival and proliferation.
Other studies investigated the biology of in vivo MSCs in host treated with chemother-
apy. In an experimental study, mice were treated with busulfan, cyclophosphamide,
cytarabine, methotrexate and bortezomib, as used clinically. The data showed that CFU-F
numbers were reduced significantly and were not recovered after 6 weeks. However,
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differentiation capacities of MSCs were not affected by these chemotherapeutic medica-
tions [208]. Furthermore, it has been shown that Wistar rats that received Doxorubicin had
BM MSCs with similar surface marker and viability to controls. However, these MSCs
demonstrated lower alkaline phosphatase production and proliferation potential [209].
11.2. Clinical/Human Studies
With regards to human studies, the numbers of BM-MSCs from patients who received
chemotherapy for BM transplantation were suppressed as indicated by significant lower
CFU-F numbers than controls. The reduction of MSC quantity was verified to be host,
not donor-related, and these patients also had a reduced bone mineral density [210].
Similarly, BM-MSCs from patients receiving high doses of chemotherapy for hematological
malignancies displayed a significant decrease in proliferative capacity. However, no
changes were detected in the expression levels of surface markers, CD105, CD44 and CD29.
Furthermore, immunofluorescent staining of alkaline phosphatase, oil red, lipoprotein
lipase, Alcian blue and aggrecan indicated preserved tri-lineage differentiation [211]. In a
study where lymphoma patients received a high-dose chemotherapy conditioning regimen
followed by autologous stem cell transplantation, BM MSCs showed reduced CFU-F
counts but preserved morphology, immunophenotype and differentiation capacity with no
differences in gene expression profile [212].
Altogether, these data suggest potential disadvantages of using autologous MSCs in
chemotherapy-treated patients for further use for ON, mainly due to reduced prolifera-
tive potential.
12. Conclusions: Challenges and Perspectives
Treatment of ON is generally challenging due to late symptoms, complicated patho-
genesis, different severity stages and multiple causes. Using MSCs in the therapy of ON is
promising, with agreement on their benefits for the early-stage ON and the value of having
adequate numbers, but there are still issues to be resolved [213]. The MSC-based therapy
for ON lacks the standardization of isolation, expansion (if cultured cells are used) as well
as transplantation/delivery methods. Another challenge is tracking and understanding
the in vivo fate of therapeutic MSCs and assessing their functional competence. Both
pre-clinical and clinical studies are needed to fill these gaps of knowledge and therapeutic
methods, respectively.
While the numbers of BM-MSCs decline with advancing age, their potential and
functionalities undergo subtle changes in vivo that might be influenced by environmental
factors such as diet, exercise and other lifestyle factors. Furthermore, individuals with
comorbidities, for example, diabetes, SLE and GD or those who chronically use GC or
alcohol, potentially have significant defective functions of MSCs. Different functional
abnormalities of MSCs were detected in secondary ON due to the etiological factors, with
some reports showing no differences between the various causes. However, it is important
to stress that future studies comparing the ON causes should consider the age and probably
gender matching as well as other technical details, e.g., fold-enrichment in BM concentrates
if these samples are analyzed for MSC quantities.
Considering the defective quality or quantity in aged or ON-related conditions, using
MSCs for ON therapy is likely to require larger or concentrated volumes of autologous BM
aspirate or biological stimulation prior to the application of autologous MSCs to achieve
successful ON treatment. In this context, new centrifugation techniques such as vertical
centrifugation could show enhanced potential to harvest more MSCs from these individu-
als [214]. Combined therapies for ON are vital to overcoming any defect in MSC functions
in these patients in order to enhance new blood vessel, bone and cartilage formation.
Growth factors and gene-editing techniques have been proposed to correct abnormalities
of these autologous MSCs before implanting them into osteonecrosis areas of the joints.
Bone morphogenetic proteins (BMPs) can facilitate the bone formation, and they have
been shown to improve the repair functions of BM-MSCs seeded in the femoral head of
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rabbits [215]. Additionally, loading β-tricalcium phosphate scaffold with BMP-2-gene-
transduced BM-MSCs was successful as a therapy for early-stage ON in goats [216]. In
terms of gene-editing, transplantation of hepatocyte growth factor transgenic autologous
BM-MSCs has been shown to promote angiogenesis and bone regeneration in a rabbit
model of hormone-induced ON [217]. Furthermore, three-dimensional (3D) bioprinting
technology is an emerging tool that holds great potential for regenerative therapies [218].
Using stem cells, 3D bioprinting can provide scaffolds that could deliver high attachment
and growth support for MSCs in a specific size and shape that fit the defective tissues.
Further attention is needed in the scaffold design to promote vascularization. Nanotech-
nology has been tested for gene delivery, scaffold fabrication and monitoring stem cell
proliferation [219]. Using nanoparticles will also enhance the monitoring of MSC fate and
promote their differentiation, thus developing regenerative therapies. However, it is still
essential to assess their safety and the best choice of materials. Future studies to test the
application of these stem cell-related technologies to treat ON would be of great value.
Autologous BM-MSCs can be delivered for regenerative therapies in their native form
within BM aspirate concentrates or after culture expansion, aiming to achieve reparative
effects with minor complications [33,200–203]. While native autologous MSCs used in BM
aspirate concentrates were found to be effective and can be readily used [220], culture-
expanded autologous MSCs have been proven safe and effective for treating ON in recent
clinical evaluations [48]. Different tissue sources of MSCs may have better potential than
BM-MSCs in conditions underlying ON, but further research is needed to confirm this idea.
An example is using reamer aspirator irrigator (RIA) waste MSCs, which are abundant and
can be functionally competent for bone regeneration [221]. Using allogeneic MSCs could be
a solution, as suggested by Chen et al., who used umbilical cord MSCs with no side effects
for ON [222], but further comparison versus autologous cells to affirm the advantages of
allogeneic cells is needed. An alternative for MSCs to enhance bone regeneration is induced
pluripotent cells (iPSCs). Recent reports indicated the capacity of iPSCs to differentiate
into osteoblasts or osteoclasts, indicating the potential value of these cells in enhancing
bone regeneration and remodeling, particularly using animal models [223]. Still, more
in vivo work is required to assess the risk of tumorgenicity and genomic instability of using
these cells. Additionally, more research is needed to provide safe and effective approaches
for promoting the therapeutic potential of iPSCs. Finally, future research should focus
on developing better animal models simulating human ON pathogenesis to enable the
application of combined therapies involving MSCs, scaffolds and growth factors. A better
understanding of compounding factors that meet the specific clinical status of ON patients
is clearly necessary for the development of personalized therapy for these patients.
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